Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Prognostic assessment after preoperative systemic therapy (PST) plays a vital role in breast cancer patients. The clinical-pathologic staging system incorporating estrogen receptor (ER)-negative disease and nuclear grade 3 tumor pathology (CPS+EG staging system) can effectively predict prognosis after PST. The Neo-Bioscore has been developed by the incorporation of the human epidermal growth factor receptor 2 (HER2) status into the CPS+EG staging system. But in a real world in China, the both staging systems had limits because of trastuzumab administration varied a lot in China from the United States. This retrospective study will validate CPS+EG and Neo-Bioscore system and explored a modified Neo-Bioscore system in multiple centers.

Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China

Validation of CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging System After Preoperative Systemic Therapy of Breast Cancer in Multi-center in China

DSS will be calculated from the time of diagnosis to death resulting from breast cancer. Patients still alive at the time of the analysis will be censored using the date they were last known to be alive.

DFS, defined as the time from the time of post-PST breast cancer surgery to local recurrence following mastectomy, local recurrence in the ipsilateral breast following lumpectomy (invasive or non-invasive), regional recurrence, distant metastasis, contralateral breast cancer (invasive or non-invasive), second primary cancer (other than squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, colorectal carcinoma in situ, or lobular carcinoma in situ of the breast), or death from any cause prior to recurrence or second primary cancer. Patients who have not had any such event at the time of data analysis will be censored at the last date they were known to be event-free.

OS will be measured as the time from the date of diagnosis to the date of death. Patients still alive at the time of the analysis will be censored using the date they were last known to be alive.

Peking University First Hospital

Associate Chief Physician of Breast Disease Center, Associate Professor, M.D.

Patients referred to the oncology / radiation oncology departments for palliative therapy.

There are no specific interventions in this observational study

no specific interventions

Stephan Gripp, Dr.

The accuracy of clinical survival estimates is tested in comparison to objective prognostic scores.

* At presentation a clinical survival estimate is obtained in each patient.
* Survival is also estimated using published prognostic scores in palliative care.
* Prognostic scores based on blood samples, general symptoms, complaints, and performance status are calculated and validated, respectively
* Each patient completes questionnaires on psychological distress
* Survival estimates are limited to 6 months.
* Each patient is followed for at least 6 months.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China	NCT03437837	Breast Cancer Neoadjuvant The... Neoplasm Stagin... Estrogen Recept... Histological Gr... HER2 Prognosis Predictive Valu...		18 Years - 75 Years	Peking University First Hospital
Prognosis and Survival Estimates in Palliative Therapy	NCT00871520	Cancer	no specific int...	18 Years -	Heinrich-Heine University, Duesseldorf

Spots Global Cancer Trial Database for predictive value of tests